REVIVA PHARMACEUTICALS HOLDINGS, INC.

Reviva Pharmaceuticals Holdings, Inc. (Nasdaq: RVPH) is a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, including schizophrenia and other neurological and psychiatric conditions. The company became a publicly traded entity through a SPAC merger transaction and filed its 10-Q with the SEC in July 2020, reflecting its status as a post-combination public company operating in the healthcare and biopharmaceutical sector. RVPH's pipeline centers on CNS-targeted therapeutics, positioning it within the specialized clinical-stage drug development space. For complete filing history, SPAC structure details, sponsor information, and real-time deal tracking on RVPH and hundreds of other SPAC transactions, sign up for full data access at SpacDesk.